雷公藤多苷联合咪唑斯汀治疗皮炎湿疹的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 雷公藤多苷联合咪唑斯汀治疗皮炎湿疹的临床观察
TITLE:
摘要: 目的:观察雷公藤多苷联合咪唑斯汀治疗皮炎湿疹的疗效和安全性。方法:138例皮炎湿疹患者随机分为对照组(69例)和观察组(69例)。对照组患者给予咪唑斯汀缓释片10 mg,口服,每日1次;观察组患者在对照组治疗的基础上给予雷公藤多苷片20~30 mg,饭后口服,每日 3次。两组疗程均为3周,治疗期间患者基本生活方式不变。观察两组患者的临床疗效,治疗前后症状总积分、白细胞介素(IL)-2、IL-6、C-反应蛋白(CRP)水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.01)。治疗后,两组患者症状总积分和IL-2、IL-6、CRP水平均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05或P<0.01)。观察组患者不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论: 雷公藤多苷联合咪唑斯汀治疗皮炎湿疹的疗效显著优于单用咪唑斯汀,且安全性较好。
ABSTRACT: OBJECTIVE: To observe the efficacy and safety of tripterygium glycosides combined with mizolastine in the treatment of dermatitis and eczema. METHODS: 138 patients with dermatitis and eczema were randomly divided into control group (69 cases) and observation group (69 cases). Control group received Mizolastine sustained release tablet 10 mg, orally, once a day. Observation group additionally received Tripterygium glycosides tablet 20-30 mg, orally taking after a meal, 3 times a day. All patients treated for 3 weeks, patients’ life way remained unchanged during treatment. Clinical efficacy, total score of symptoms, IL-2, IL-6, CRP levels and the incidence of adverse reactions in 2 groups were observed. RESULTS: The total effective rate in observation group was significantly higher than control group, with significant difference (P<0.01). After treatment, the total score of symptoms, IL-2, IL-6, CRP levels in 2 groups were significantly lower than before, and observation group was lower than control group, with significant differences (P<0.05 or P<0.01). The incidence of adverse reactions in observation group was significantly lower than control group, with significant difference (P<0.05). CONCLUSIONS: Tripterygium glycosides combined with mizolastine shows better efficacy than mizolastine alone in the treatment of dermatitis and eczema, with better safety.
期刊: 2016年第27卷第27期
作者: 巫艳芬,刘永军,梁进
AUTHORS: WU Yanfen,LIU Yongjun,LIANG Jin
关键字: 雷公藤多苷;咪唑斯汀;皮炎湿疹;疗效;安全性
KEYWORDS: Tripterygium glycosides; Mizolastine; Dermatitis and eczema; Efficacy; Safety
阅读数: 380 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!